Why Canada Leaped Ahead of US in COVID-19 Vaccinations

VANCOUVER, CANADA – When the COVID-19 vaccines started rolling out across the United States, Canada was short of supply and its leaders faced harsh criticism for not being better prepared. Expected deliveries from Europe were delayed and the country had no capability to produce its own vaccines.

By mid-July, that changed. More doses of vaccines started to arrive and Canada quickly passed the United States in vaccination rates.

As of Wednesday, 71.4% of Canadians had received at least one dose, with 57.6% having received two doses. In the United States, by comparison, 57.7% had received the first dose and 49.8% the second.

It was a different story three months earlier, when the United States had inoculated 43.2% with one dose and 29.9% were fully vaccinated with two doses. In Canada at that time, 31.3% had received a first dose and only 2.8% had gotten the second.

All vaccines being used in Canada — Pfizer, Moderna and AstraZeneca — require two doses. The single-dose Johnson & Johnson vaccine is approved but has not yet been utilized.

 

Dr. Brian Conway, the medical director of the Vancouver Infectious Diseases Center, believes Canada has overtaken the U.S. in vaccinations because its political leaders are in greater agreement about the value of the vaccines than their southern neighbors.

“All politicians of all stripes, in terms of major political parties, and even minor political parties, have been supportive of the vaccination program. And within the next couple of weeks, 80% of eligible Canadians aged 12 and up will be doubly vaccinated,” Conway said.

 

Nazeem Muhajarine, an epidemiologist at the University of Saskatchewan in Saskatoon and part of a national research committee on COVID-19 variants, echoes Conway and says Canadians themselves have approached vaccinations with more unity.

“The sense of, you know, that you are part of a collective purpose versus kind of, you know, you being an individual person, individual rights and responsibilities, which is so important in the U.S., is not as important here,” Muhajarine said.

 

“So added this extra incentive for people, which is not just protect yourself or others, but also to get your province over the percentage that you need to keep going on a reopening plan,” Tworek said.

Many public health officials across Canada are starting to wind down mass vaccination clinics and are now going to beaches, farmers markets, summer fairs and sporting events.

It is hoped this will not only motivate more people to get vaccinated, but also make it easier to get the vaccine, especially for those in more remote communities or facing other challenges.

 

 

Source: Voice of America

Florida Sets Daily Record of More Than 21,000 COVID-19 Cases

Florida reported a record 21,683 COVID-19 cases on Saturday, making the Southeastern U.S. state the national epicenter of the coronavirus pandemic, the U.S. Centers for Disease Control and Prevention said.

The state’s previous record was 19,334 cases reported on January 7, before vaccinations had become widely available, according to federal health data, The Associated Press reported.

Florida, with a population of nearly 21.5 million people, now accounts for about one-fifth of all new COVID-19 cases in the U.S., the CDC said. The state had reported about 17,000 new cases on Friday, the same day state Governor Ron DeSantis barred schools from requiring that students wear masks when they return to in-person classes in August.

AdventHealth, one of the state’s largest health care systems, said on Friday that its Central Florida Division would not perform nonemergency surgeries in an effort to conserve resources because of the increase in COVID-19 patients in the region.

Since the start of the pandemic, Florida has recorded 2.6 million confirmed COVID-19 cases and more than 39,000 deaths, according to the Johns Hopkins University Coronavirus Resource Center.

Cruises return

The cruise ship industry, which is a big part of Florida’s tourism industry, was hit hard when the pandemic began in early 2020. On Saturday, the Carnival Cruise Line’s Mardi Gras ship was to set sail from Port Canaveral, Florida, the first ship since March 2020.

The ship, planning a seven-day voyage to the Caribbean, was running at just 70% of its normal 5,282-passenger capacity.

The pandemic forced cruise lines to suspend trips leaving from U.S. ports. Carnival Cruise Line is requiring — at least for its July and August voyages — that 95% of its passengers and crew be vaccinated, according to the AP.

A day earlier, Royal Caribbean announced that six passengers — four fully vaccinated adults and two unvaccinated minors — had tested positive for COVID-19. All six were Americans, Royal Caribbean spokesperson Lyan Sierra-Caro told the AP. She said the six, who were not all traveling together, had disembarked in Nassau, the Bahamas, after a seven-day cruise. Royal Caribbean planned to fly the six back to the U.S. on private transportation, Sierra-Caro said, according to the AP.

 

Florida also is home to several major theme parks, including Walt Disney World, Universal Orlando Resort and SeaWorld. On Saturday, Universal and SeaWorld began asking guests to wear masks indoors. Universal also is requiring employees to wear masks while indoors and to practice social distancing protocols.

“The health and safety of our guests and team members is always our top priority,” Universal said in a statement.

On Friday, the Walt Disney Co. started requiring employees and guests older than 2 to wear masks indoors and on Disney transportation and said it would be requiring all salaried and nonunion employees who work at its properties in the U.S. to be fully vaccinated. As of now, face coverings are not required outdoors at the parks.

 

Those Disney employees who are unvaccinated will have 60 days to receive the shots.

Across the country, the state of Arizona, in the U.S. Southwest, is dealing with a worsening outbreak caused by the delta variant of the coronavirus, as well as low vaccination rates in the state, health officials said.

“Unlike last summer when we were headed into school w/ declining rates, the match has been lit and the kindling is aflame this time,” Dr. Joe K. Gerald, a University of Arizona researcher who tracks COVID-19 data, said on Twitter, according to AP.

The state reported more than 2,000 new daily COVID-19 cases for the first time in nearly five months, according to an AP report. The number of hospitalized COVID-19 patients topped 1,000 for a third straight day as well, according to officials.

Arizona, with a population of 7.2 million, has reported 925,169 confirmed cases of COVID-19 and 18,224 deaths since the pandemic began, according to Johns Hopkins.

Vaccine distribution

The CDC also reported that as of Saturday, the U.S. had distributed 400.6 million vaccine doses and had administered 345.6 million doses of COVID-19 vaccines, which include the two-dose Pfizer and Moderna and the one-dose Johnson & Johnson.

More than 190.8 million people had received at least one dose of the vaccine, while more than 164.4 million had been fully vaccinated as of Saturday.

As of Saturday, 197.7 million cases of COVID-19, the disease caused by the coronavirus, and 4.2 million deaths had been recorded globally, according to Johns Hopkins. The U.S. led the world in number of COVID-19 cases, with nearly 35 million, and related deaths, 613,113, according to the university.

 

 

Source: Voice of America

 

UL collabore avec WIZZIT Digital pour faire progresser les paiements de détail en Afrique subsaharienne avec le lancement d’une solution de paiement mobile SoftPOS avec PIN

UL et WIZZIT Digital contribuent à accélérer le déploiement des paiements sans contact pour favoriser l’inclusion financière et permettre aux commerçants de toutes tailles de réaliser leurs ambitions.

JOHANNESBURG, le 31 juillet 2021 /PRNewswire/ — UL, le leader mondial des sciences de la sécurité, a annoncé que WIZZIT Digital, une société de paiements numériques, a lancé une solution logicielle de point de vente (SoftPOS) Tap2Pay avec prise en charge de la saisie du numéro d’identification personnel (PIN). Cette solution permet de transformer des appareils commerciaux (COTS) en terminaux de paiement de point de vente (POS). Tap2Pay est la première solution SoftPOS développée en Afrique du Sud qui prend en charge la saisie du code PIN et est reconnue par Visa et Mastercard. WIZZIT Digital est désormais opérationnel avec un premier client de lancement, l’une des plus grandes banques commerciales panafricaines.

UL has announced that WIZZIT Digital has launched a Tap2Pay software point-of-sale (SoftPOS) solution with personal identification number (PIN) entry support. This solution transforms commercial off-the-shelf (COTS) devices into point-of-sale (POS) payment terminals. Tap2Pay is the first SoftPOS solution developed in South Africa that supports PIN entry and is recognized by Visa and Mastercard. (PRNewsfoto/UL)

Pour surmonter les difficultés liées à la mise sur le marché d’une solution SoftPOS, UL a soutenu la solution Tap2Pay depuis son développement jusqu’à son entrée sur le marché. Dans un premier temps, UL a fourni des services de conseil pour aider WIZZIT Digital à s’orienter dans le paysage réglementaire des paiements et à répondre aux exigences des systèmes de paiement. Lorsque Tap2Pay a été prêt pour les tests fonctionnels, UL l’a testé avec une série d’outils accrédités par le système afin de fournir un retour sur les problèmes potentiels. Après le débogage et le dépannage, UL a fourni des services de tests fonctionnels et a aidé WIZZIT Digital à obtenir l’approbation du type pilote Visa. Après l’approbation fonctionnelle, les laboratoires de sécurité d’UL ont évalué la solution pour les programmes pilotes de sécurité de Mastercard et de Visa. Ces tests et évaluations par rapport aux exigences du projet ont permis à WIZZIT de mettre la solution sur le marché.

L’évaluation d’UL a confirmé que la solution Tap2Pay répondait aux principales exigences de sécurité avant d’entrer sur le marché. Il s’agissait notamment d’aider à affirmer la sécurité des données de paiement obtenues par une interface de communication en champ proche (NFC) et un noyau sans contact du dispositif COTS. Les mécanismes de sécurité, les contrôles et les mesures d’atténuation de la solution protègent les données du compte du consommateur et d’autres actifs.

Tap2Pay entre sur le marché à un moment où la demande de solutions de paiement sans contact augmente. Selon Deloitte, la pandémie de COVID-19 a rendu le besoin de numérisation des paiements plus critique que jamais. Cependant, de nombreux marchés émergents sont confrontés à des problèmes d’acceptation des cartes. Deloitte a également noté qu’en Afrique du Sud, environ 90 % des 100 000 magasins du secteur informel n’acceptent que des espèces. Pour répondre à la demande des clients et accroître l’acceptation des cartes par le marché des petites entreprises, y compris les commerçants des zones rurales, il faut une solution abordable.

UL Logo (PRNewsFoto/UL) (PRNewsFoto/UL)

Jako Fritz, conseiller principal en matière de sécurité chez UL, a déclaré : « SoftPOS est une approche entièrement nouvelle des paiements numériques qui réduit la barrière d’entrée pour les commerçants afin d’accepter les transactions par carte sans contact. L’informatique cloud, ainsi que le protocole Europay, MasterCard et Visa, permettent de passer du traditionnel point de vente physiquement sécurisé au traitement des transactions par logiciel COTS. Ces solutions aideront les propriétaires de micro-entreprises et de petites entreprises ainsi que les commerçants du monde entier à répondre aux exigences d’une société de plus en plus dépourvue de numéraire, de manière plus sûre et avec un investissement minimal. »

Expliquant comment Tap2Pay répond à un besoin non satisfait du marché, Brian Richardson, PDG et cofondateur de WIZZIT Digital, a déclaré : « Depuis près de deux décennies, nous travaillons avec des banques et des institutions financières sur les marchés émergents, y compris de nombreux pays d’frique. Notre expérience nous a appris deux choses. Tout d’abord, les consommateurs et les banques veulent la protection d’un code PIN lorsqu’ils effectuent des transactions sans contact. Dans un contexte de cyberfraude croissante, le code PIN offre un niveau de sécurité universellement accepté et auquel les gens font confiance. Deuxièmement, les solutions traditionnelles de paiement sans espèces sont trop coûteuses pour les micro et petits commerçants.

« Pour les petits commerçants, l’investissement initial dans les terminaux et les coûts de maintenance permanents sont tout simplement trop élevés. Tap2Pay SoftPos with PIN supprime cette barrière, permettant aux commerçants de toute taille d’accepter les paiements sans espèces. Cela leur permettra en fin de compte d’attirer davantage de clients, y compris ceux qui ne veulent pas payer en liquide des biens et des services, pour une fraction du coût », a déclaré M. Richardson.

À propos d’UL
UL est le leader mondial des sciences de la sécurité. Nous fournissons des services de test, d’inspection et de certification (TIC), de formation et de conseil, des solutions de gestion des risques et des informations commerciales essentielles pour aider nos clients, basés dans plus de 100 pays, à atteindre leurs objectifs de sécurité et de durabilité. Notre connaissance approfondie des produits et notre intelligence des chaînes d’approvisionnement font de nous le partenaire de choix des clients confrontés à des défis complexes. Découvrez-en davantage sur UL.com.

Pour en savoir plus sur le développement des normes et les autres activités à but non lucratif, visitez le site UL.org.

Contacts avec la presse :
Steven Brewster
UL
ULNews@UL.com
+1.847.664.8425

Christina Bostock
IHC
christina@ih-c.com
971.55.887.3054

Photo – https://mma.prnewswire.com/media/1578854/UL_Wizzit.jpg
Logo – https://mma.prnewswire.com/media/325015/ul_enterprise_logo.jpg

CDC: Delta Variant Infections in Vaccinated People May Be as Transmissible as in Unvaccinated

The U.S. Centers for Disease Control and Prevention says the delta variant of the coronavirus is as contagious as chickenpox and that infections in vaccinated people may be as transmissible as in the unvaccinated.

Internal CDC documents, first obtained by The Washington Post, urged staff to “acknowledge the war has changed” in light of the delta variant.

The CDC said the variant requires a new approach to help the public understand the danger, adding that evidence shows the delta variant may pose a greater risk for hospitalization and death.

The agency also emphasized that vaccines are highly effective at preventing infections, severe disease and death. The CDC said that while the vaccinated are less likely to get sick, they might be just as likely as those who are unvaccinated to pass the disease to others.

 

Top U.S. infectious disease expert Dr. Anthony Fauci said during an interview Friday with Reuters that he hopes regulators will grant full approval for COVID-19 vaccines as soon as next month. He said the move could encourage more Americans to get the shots, which are currently authorized on an emergency-use basis by the U.S. Food and Drug Administration.

U.S. President Joe Biden announced Thursday that civilian federal government employees must be vaccinated or submit to regular testing and wear masks.

Top U.S. infectious disease expert Dr. Anthony Fauci said during an interview Friday with Reuters that he hopes regulators will grant full approval for COVID-19 vaccines as soon as next month. He said the move could encourage more Americans to get the shots, which are currently authorized on an emergency-use basis by the U.S. Food and Drug Administration.

U.S. President Joe Biden announced Thursday that civilian federal government employees must be vaccinated or submit to regular testing and wear masks.

Saitama, Chiba, Kanagawa and Osaka are the new prefectures to be under the state of emergency. Several other prefectures will be placed under pre-emergency measures.

Under a state of emergency, business is suspended in locations that serve alcohol or have karaoke. Under pre-emergency measures, businesses are asked not to serve alcohol.

Japan reported more than 10,000 daily coronavirus cases Thursday, the first time the country’s daily count exceeded 10,000.

Around the globe

In Israel, health officials began administering coronavirus booster shots Friday to people older than 60 who have been fully vaccinated in an effort to stop a recent spike in cases.

Italy’s Health Institute announced Friday that the delta variant accounted for almost all new COVID-19 cases in the country at nearly 95% of cases as of July 20.

German officials announced Friday that unvaccinated travelers arriving in the country will need to present a negative COVID-19 test result.

 

WHO Director-General Tedros Adhanom Ghebreyesus told a news conference from Geneva on Friday that “hard-won gains are in jeopardy of being lost” because of the delta variant.

WHO officials have said they fear that 47 of Africa’s 54 countries will miss a September target of vaccinating 10% of their populations, a goal set earlier this year by the World Health Assembly, the world’s highest health policy-setting body. Africa accounts for less than 1% of the more than 4 billion vaccine doses administered globally.

Overall, around the globe, just 1.1% of people in low-income countries have received at least one vaccine dose.

The Johns Hopkins Coronavirus Resource Center reported Friday more than 197 million global COVID infections and more than 4.2 million deaths from the disease worldwide.

 

 

Source: Voice of America

Malawi Ready to Store, Distribute Incoming COVID-19 Vaccine: Official

BLANTRYE, MALAWI – Malawi expects to receive more than 600,000 doses of COVID-19 vaccine soon. In May, the country had to discard 20,000 doses due to a lack of demand. But officials say that when the new vaccine arrives, demand will be high and Malawi will be prepared.

Over the next two months, Malawi is expected to receive about 372,000 doses of the Pfizer vaccine and about 300,000 doses of the Johnson & Johnson vaccine.

Experts are warning the country needs to be ready to store and distribute it.

In May, authorities burned about 20,000 expired doses of the AstraZeneca vaccine that went unused due to a shortage of distribution centers and widespread vaccine hesitancy, the latter caused by myths and misinformation about their safety.

 

Queen Dube is chief of health services in Malawi’s Ministry of Health. She said there will be no repeat of that incident, because a government campaign has now convinced Malawians the vaccines are safe and protective.

She notes that a recent consignment of 192,000 AstraZeneca vaccines, which the country received last Saturday were gone within days.

Even if some of the donated vaccines are due to expire soon, they will be distributed within sufficient time, she said.

“It’s this scenario where you have one week of shelf-life left that puts you in very difficult circumstances,” Dube said. “But, you know, we have created demand. Remember on 27th [July] we vaccinated 75,000 people and so even if we had all those doses that were to expire in two weeks, say for example 100,000 doses, we should be able to quickly use them within two, three days.”

Dr. Alinafe Kasiya is a public health expert with Village Reach, an international health charity that is supporting vaccine delivery in African countries.

He said countries need to think about their storage and distribution systems.

“That means a number of things; Do we have enough capacity to be able to store the vaccines that are coming?” Kasiya said. “I mean some of the vaccines might have different cold chain requirements. But also do we have a logistic system in place to be able to move these vaccines around? Do we have enough people trained? Are we opening up enough sites? Are we looking at doing more to create demand?”

Kasiya, the country director for Village Reach in Malawi, applauds Malawi’s government for creating demand for the vaccine.

Queen Dube says even though the Pfizer vaccine needs ultra-cold storage, no doses will be wasted.

“There are two things with Pfizer,” Dube said. “We now have evidence that if you take it out of an ultra-cold system you can store it at temperatures between two to eight degrees. These are normal temperatures that we store our vaccines in; and you can use it for 31 days.”

So far, Malawi has recorded about 51,000 cases of COVID-19 and nearly 1,600 deaths. Only a tiny fraction of the country’s 18 million people have been inoculated, though that number will quickly rise if more people cooperate with the government’s vaccination campaign.

 

 

 

Source: Voice of America

 

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines

Dubai, United Arab Emirates, July 30, 2021 (GLOBE NEWSWIRE) — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan. Takeda will retain commercialization rights in Japan and HilleVax will integrate certain Japan development activities into its global development. Takeda remains committed to vaccines and this collaboration allows Takeda to focus primarily on dengue, COVID-19, pandemic influenza and Zika.

HIL-214, which is a virus-like particle (VLP) based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in 4,712 adult subjects in which HIL-214 was well-tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis from norovirus infection.1 To date, the candidate has been studied in nine human clinical trials with safety data from over 4,500 subjects and immunogenicity data from over 2,000 subjects.

Ursula Belinda Myles, General Manager of Takeda’s Access Market Cluster (covering much of Africa) commented: “Africa’s underlying burden of endemic diseases is one of the largest in the world, and infectious diseases play a larger portion of these diseases across the continent. Like many other nations, COVID-19 has emphasized Africa’s greatest challenges around healthcare and highlighted the need for continued greater investment in healthcare systems. These investments are critical to secure economic development as Africa implements flagship projects around the 2030 Africa Health Strategy.”

Ursula added: “The announcement of our partnership with Frazier Healthcare Partners will allow Takeda to focus efforts and resources on vaccines for diseases prevalent across Africa and provide support in alleviating the growing burden that infectious diseases have on public health systems.”

Norovirus is a common intestinal infection marked by diarrhea, vomiting, abdominal cramps, nausea and sometimes fever that may lead to clinically significant dehydration.2 Norovirus is recognized as the leading cause of acute gastroenteritis across the age spectrum.3 It is estimated that norovirus causes nearly 700 million cases of illness and more than 200,000 deaths worldwide per year with significant additional economic and social burden.3 No vaccines are currently approved for norovirus infection, and HIL-214 continues to be the most advanced norovirus vaccine candidate in human clinical trials.

“Takeda and Frazier have a history of successfully partnering together, and we are confident in HilleVax’s capabilities to progress HIL-214, the most advanced norovirus vaccine candidate in development with the potential to address the huge global burden of norovirus-associated acute gastroenteritis,” said Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda. “This will allow Takeda to focus its efforts and resources on our dengue vaccine, which we have begun filing for licensure around the world, our pandemic programs, and our partnership with the US Government to develop a Zika vaccine

 Takeda’s Commitment to Vaccines

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health. For more than 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, COVID-19, pandemic influenza and Zika. Takeda’s team brings an outstanding track record and a wealth of knowledge in vaccine development and manufacturing to advance a pipeline of vaccines to address some of the world’s most pressing public health needs. For more information, visit www.TakedaVaccines.com.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

About Frazier Healthcare Partners

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe. For more information about Frazier Healthcare Partners, visit the company’s website at http://www.frazierhealthcare.com.

About HilleVax

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates.  Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Takeda Pharmaceutical Company Limited Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 CONTACTS:

Takeda Media Contacts:
Japanese Media

Ryoko Matsumoto

ryoko.matsumoto@takeda.com

+81 (0) 3-3278-3414

edia Outside Japan

Amy Atwood

amy.atwood@takeda.com

+1-774-571-3316

For HilleVax, Inc.: For Frazier Healthcare Partners:
David Socks

info@hillevax.com

+1-650-325-5156

Liz Park

liz.park@frazierhealthcare.com

+1-650-319-1831

References

1 Sherwood J, et al. Vaccine 2020; 38(41):6442-6449

2 https://ww.cdc.gov/norovirus/index.html [accessed 2021 April 27].

3 Hall AJ, et al. Expert Rev Vaccines 2016;15(8):949-951

Mohammed Al Nasseri
Takeda Pharmaceuticals
+971507694646
Mohammed.alnasseri@fleishman.com

L’industrie chinoise des circuits intégrés accélère la production avancée de puces (expert)

BEIJING, 30 juillet 2021 /PRNewswire/ — Article publié sur China.org.cn.

L’industrie chinoise des circuits intégrés est en train de passer d’un développement à grande vitesse à un développement de grande qualité, alors que les procédés nationaux et plus avancés de fabrication de puces font des percées dans l’ensemble de la chaîne industrielle, a déclaré un expert.

Dans un article publié au début du mois sur Guancha.cn, un agrégateur d’informations et de commentaires en ligne basé à Shanghai, le Dr Bao Yungang, vice-directeur de l’Institut des technologies informatiques (ICT) de l’Académie chinoise des sciences (CAS), a noté que les procédés chinois de fabrication de puces en 14 nm et 28 nm gagnaient du terrain et étaient utilisés pour de nombreuses applications dans divers domaines.

China's homegrown AI chips are on display at the 2021 World Artificial Intelligence Conference in Shanghai, July 7, 2021. [Photo/VCG]

Le processus de fabrication des puces en 14 nm du pays a surmonté de nombreuses difficultés technologiques grâce à des améliorations significatives des techniques de fabrication, des technologies de conditionnement et des matériaux d’équipement clés, a déclaré M. Bao.

Il a ajouté que le nœud de 14 nm est le procédé de fabrication de puces le plus largement utilisé dans des domaines tels que l’électronique grand public haut de gamme, l’informatique à haut débit, l’intelligence artificielle et l’automobile.

Selon les statistiques, le marché mondial des semi-conducteurs a réalisé environ 200 milliards de dollars de ventes au premier semestre 2019. Le procédé de fabrication de puces en 14 nm a représenté 65% de ces ventes.

M. Bao a déclaré que la Chine était désormais en mesure de produire en masse des puces en 28 nm, alors que le pays a réalisé d’importants progrès dans le développement de certains équipements et matériels essentiels.

28 nm est la ligne de démarcation entre la fabrication de circuits intégrés (CI) de basse à moyenne gamme et de milieu à haut de gamme, a-t-il expliqué.

Outre les puces pour les processeurs, les cartes graphiques et l’intelligence artificielle (IA), d’autres produits industriels courants tels que les télévisions, les climatiseurs, les automobiles, les trains à grande vitesse, les satellites, les robots industriels, les ascenseurs et les drones sont les applications les plus courantes pour le processus technologique de 28 nm, a ajouté M. Bao.

« La Chine doit de toute urgence se diriger vers la production de puces haut de gamme, car être capable de produire des puces en 28 nm signifie qu’elle peut répondre à la majeure partie de la demande de puces sans compter sur d’autres pays », a-t-il souligné.

En 2019, la capacité de production des circuits intégrés pour les procédés de pointe (<10 nm) ne représentait que 4,4% de la capacité installée dans l’ensemble du secteur, tandis que les procédés supérieurs à 28 nm représentaient 52% de la part globale, selon le rapport « Global Wafer Capacity 2020-2024 » publié par IC Insights.

Alors que les procédés de fabrication de puces en 14 nm et 28 nm peuvent répondre à une grande partie de la demande intérieure, la Chine s’efforce de promouvoir des procédés de pointe afin de s’affranchir progressivement de sa dépendance vis-à-vis de l’étranger.

Wen Xiaojun, directeur de l’Institut de l’information électronique au Centre chinois pour le développement de l’industrie de l’information (CCID), a déclaré au portail d’information chinois huanqiu.com, que le procédé national de fabrication de puces en 14 nm devrait être produit en masse d’ici l’année prochaine.

En tant que plus grand marché mondial de semi-conducteurs, la Chine a investi considérablement dans l’acquisition de semi-conducteurs et dans le recrutement de talents afin de soutenir l’industrie de la fabrication de puces et la rendre identique à celle des meilleures fonderies du monde.

Un rapport de Goldman Sachs publié l’année dernière prévoit que la Chine devrait être en mesure de produire des puces de 7 nm d’ici 2023.

Étant donné la dynamique du secteur de la production de puces, les opérateurs de communication nationaux, les fournisseurs d’équipements et les fournisseurs de services de communication doivent étudier de nouveaux modes de service tout en innovant l’architecture des appareils pour gagner la confiance des clients et stimuler les progrès technologiques, a noté M. Bao.

Selon lui, la clé pour arriver à de nouvelles avancées réside dans une meilleure intégration au sein du système mondial d’innovation et de collaboration, car « l’industrie des circuits intégrés est vraiment une industrie mondiale et aucun pays ne doit être isolé de la chaîne industrielle ».

Photo – https://mma.prnewswire.com/media/1583059/China_org_cn.jpg

‫مارغريت كروتي تتولى قيادة شركة جون سنو (JSI) ومجموعة وكالات ورلد إيديوكيشن العالمية

بوسطن, 29 يوليو 2021 /PRNewswire/ — أعلن مجلس إدارة شركة جون سنو عن تعيين مارغريت كروتي في منصب رئيس الشركة والرئيس التنفيذي القادم. وستخلف جويل لامستاين، الذي شغل منصب رئيس الشركة والرئيس التنفيذي منذ تأسيسه شركة جون سنو بالتعاون مع بيرت هيرشهورن في عام 1978.

John Snow, Inc. Logo

ستتولى مارغريت رئاسة شركة جون سنو الربحية ومؤسسة جون سنو غير الهادفة للربح للأبحاث والتدريب ومؤسسة ورلد إيديوكيشن غير الهادفة للربح التابعة لها، نظرًا لما تحظى به من سجل حافل من القيادة والابتكار في القطاع غير الهادف للربح والقطاع الخاص على حد سواء في مجالات التعليم والصحة العامة.

ستنضم مارغريت إلى شركة جون سنو وورلد إيديوكيشن في يناير 2022 من منصبها رئيسًا تنفيذيًا لمؤسسةPartnership with Children، وهي شركة تقدم خدمات الصحة المجتمعية وإدارة المدارس المجتمعية في مدينة نيويورك.

وقد علق جويل قائلًا: وجدنا في مارغريت شخصًا لديه معرفة بمجالات التنمية الاجتماعية والصحة الدولية والمحلية في الولايات المتحدة ورؤية ستساعد على النهوض بمؤسسة جون سنو والتعليم العالمي إلى المستقبل، مع رعاية الثقافة التي تشتهر بها مؤسسة جون سنو.

لقد قادت مارغريت سابقًا مبادرة إنقاذ الأطفال للحد من وفيات الأطفال والأمهات على الصعيد العالمي. كما أمضت سبع سنوات في مؤسسة إي إف التعليم أولًا (EF Education) وعملت في شركة ماكينزي وشركاه في جاكرتا بإندونيسيا.

تخرجت مارغريت من جامعة برينستون بدرجة البكالوريوس في التاريخ والدراسات الأميركية الأفريقية، وحصلت على ماجستير في إدارة الأعمال من كلية هارفارد للأعمال وماجستير في الصحة العامة من جامعة كولومبيا. وهي تعمل في العديد من مجالس الصحة والتعليم، بما في ذلك مجالس الصحة في شبكة نورثويل هيلث، والمعهد الطبي المفتوح، وكلية الدراسات العليا للصحة العامة في جامعة المدينة، وسي تشانغ كابيتال بارتنرز، وصندوق المستشفيات المتحدة، ومنظمة أكسيس هيلث إنترناشيونال. وهي عضو في مجلس العلاقات الخارجية ومنظمة الرؤساء الشباب، وتعمل في العديد من فرق العمل الحكومية والمجالس الاستشارية للتعليم العالي، وترأس برنامج القادة الناشئين للقادة الشباب في القطاع الاجتماعي.

اطلع على الإعلان بالكامل.

تعتبر شركة جون سنووالشركة الفرعية غير الربحية التابعة لها، ومعهد جون سنو للأبحاث والتدريب، منظمات استشارية عالمية في مجال الصحة العامة تُكرس جهودها لتعظيم المساواة في خدمات الصحة وتحسين صحة الأفراد والمجتمعات، وتوفير بيئة حيث يمكن للأفراد المتحمسين متابعة هذه القضية.

للتواصل:
ماري كاثرين أراندا
mary-kathryn_aranda@jsi.com

الشعار- https://mma.prnewswire.com/media/1583410/JSI_Logo_Logo.jpg